Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.
Read the full articleYou might also wanna read
J&J Stock Slips Despite Earnings Beat as Company Raises Guidance Toward $100 Billion Sales Milestone Today
Johnson & Johnson's stock fell despite exceeding Q2 earnings expectations, as investor optimism had already been priced in. The company rais
Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Investors didn't seem to think so after the company published it.
Why Johnson & Johnson (JNJ) Stock Declined Despite Strong Q2 Earnings Beat
Johnson & Johnson (JNJ) shares fell 2% despite beating Q2 estimates with $2.90 EPS and $25.31B revenue, while raising full-year guidance on
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have histor
Major Earnings Reports Expected: Johnson & Johnson (JNJ) and More
Related Stocks: JNJ
Healthcare Stocks: J&J, UnitedHealth, Abbott Face Test on Sector’s 9% Earnings Drop
NEW YORK, July 12, 2026, 4:33 p.m. EDT — Healthcare stocks head into the week with Johnson & Johnson, UnitedHealth and Abbott set to gauge w
Comments
Sign in to join the conversation.
No comments yet. Be the first.